Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Blood

• Publication date

  1987-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V70.4.1014.BLOODJOURNAL7041014PMID 3115331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating haematopoietic progenitors in myelofibrosis.

  2009cited by this paper
• Granulocyte-committed progenitor cells in the blood of patients with myelosclerosis.

  2009cited by this paper
• Gamma-interferon inhibits collagen synthesis in vivo in the mouse.

  1987cited by this paper
• Clinical toxicity of interferons in cancer patients: a review.

  1986cited by this paper
• Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

  1986cited by this paper
• Multilineage expression of haemopoietic precursors with an abnormal clone in idiopathic myelofibrosis

  1986cited by this paper
• Myelofibrosis: a role for platelet derived growth factor (PDGF)?

  1986cited by this paper
• Studies of interferon as a regulator of hematopoietic cell proliferation.

  1985cited by this paper
• Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo.

  1985cited by this paper
• Release of granulocyte-macrophage colony stimulating factors from major histocompatibility complex class II antigen-positive monocytes is enhanced by human gamma interferon.

  1985cited by this paper
• Immune interferon: a pleiotropic lymphokine with multiple effects.

  1985cited by this paper
• Megakaryocytic cells in mixed haemopoietic colonies (CFU‐GEMM) from the peripheral blood of normal individuals

  1985cited by this paper
• Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes.

  1985cited by this paper
• FIBROSIS OF THE BONE MARROW: CONTENT AND CAUSES

  1985cited by this paper
• The synergistic influence of human interferon-gamma and interferon-alpha on suppression of hematopoietic progenitor cells is additive with the enhanced sensitivity of these cells to inhibition by interferons at low oxygen tension in vitro.

  1985cited by this paper
• Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders

  1984cited by this paper
• Differences among myeloproliferative disorders in the behavior of their restricted progenitor cells in culture.

  1983cited by this paper
• The Syndrome of Idiopathic Myelofibrosis: A CLINICOPATHOLOGIC REVIEW WITH EMPHASIS ON THE PROGNOSTIC VARIABLES PREDICTING SURVIVAL

  1983cited by this paper
• Circulating granulocyte and macrophage progenitor cells in primary and secondary myelofibrosis

  1983cited by this paper
• Monoclonal antibodies against human platelet glycoprotein IIIa

  1983cited by this paper
• Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders

  1983cited by this paper
• Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells.

  1983cited by this paper
• Effect of interferon on pluripotent hemopoietic progenitors (CFU-GEMM) derived from human bone marrow.

  1982cited by this paper
• Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders.

  1982cited by this paper
• Pathophysiological mechanisms operating in the development of myelofibrosis: role of megakaryocytes.

  1982cited by this paper
• Interferons: biochemical, cell growth inhibitory, and immunological effects.

  1981cited by this paper
• Evidence that types I and II interferons have different receptors

  1981cited by this paper
• Erythropoiesis in Myelofibrosis with Myeloid Metaplasia: Recognition of Different Classes of Patients by Erythrokinetics

  1981cited by this paper
• Origin of Human Bone Marrow Fibroblasts

  1980cited by this paper
• The pathogenesis of myelofibrosis in myeloproliferative disorders.

  1980cited by this paper
• Endogenous erythroid colony formation by peripheral blood mononuclear cells from patients with myelofibrosis and polycythemia vera.

  1979cited by this paper
• Identification of megakaryocytes, macrophages, and eosinophils in colonies of human bone marrow containing neurtophilic granulocytes and erythroblasts.

  1979cited by this paper
• Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia

  1978cited by this paper
• DEMONSTRATION OF CELL SURFACE ANTIGENS AND THEIR ANTIBODIES BY THE PEROXIDASE‐ANTIPEROXIDASE METHOD

  1978cited by this paper
• THE PATHOGENESIS OF MYELOPROLIFERATIVE SYNDROMES

  1978cited by this paper
• Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.

  1978cited by this paper
• Increased erythrocytic and neutrophilic progenitors in myelofibrosis with myeloid metaplasia.

  1976cited by this paper
• Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia.

  1975cited by this paper
• Studies of leukemic cell populations in culture.

  1974cited by this paper
• The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.

  1971cited by this paper

• Pegylated interferon: the who, why, and how.

  2024cites this paper
• Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment

  2022cites this paper
• Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature

  2020cites this paper
• Thrombocytosis

  2019cites this paper
• The Rationale for Immunotherapy in Myeloproliferative Neoplasms

  2019cites this paper
• Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

  2018cites this paper
• The Changed Proportion of CD45RA+/CD45RO+ T Cells in Chronic Hepatitis C Patients During Pegylated Interferon-α with Ribavirin Therapy

  2017cites this paper
• Mobilisation and dysfunction of haematopoietic stem/progenitor cells after Listonella anguillarum infection in ayu, Plecoglossus altivelis

  2016cites this paper
• Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?

  2016cites this paper
• Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

  2016cites this paper
• PRİMER MİYELOFİBROZİS: PATOGENEZ, TEŞHİS VE TEDAVİDE GÜNCEL BİLGİLER

  2015cites this paper
• High spontaneous granulocyte/macrophage-colony formation in patients with myelofibrosis.

  2014cites this paper
• The role of cytokines in the initiation and progression of myelofibrosis.

  2013cites this paper
• CYTOKINES AND INTERFERONS

  2013cites this paper
• Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms

  2013cites this paper
• hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) recombinant interferon-alpha on chronic myelogenous leukemia Synergistic antiproliferative effect of recombinant interferon-gamma with

  2013cites this paper
• JAK2V617F-positive Myeloproliferative Neoplasms : KI mouse models, Interferon-α therapy and clonal architecture

  2013cites this paper
• Pharmacotherapy of polycythemia vera

  2013cites this paper
• Altered Thymic Function during Interferon Therapy in HCV-Infected Patients

  2012cites this paper
• Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.

  2011cites this paper
• Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.

  2010cites this paper
• 干扰素-α靶向JAK2V617F阳性造血祖细胞并通过p38 MAPK途径发挥作用

  2010cites this paper
• Myeloproliferative neoplasms: new translational therapies.

  2010cites this paper
• Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

  2009cites this paper
• Choosing between stem cell therapy and drugs in myelofibrosis

  2008cites this paper
• Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

  2008cites this paper
• Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

  2008cites this paper
• SPOTLIGHT REVIEW Interferon-a therapy in bcr-abl-negative myeloproliferative neoplasms

  2008cites this paper
• Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.

  2007cites this paper
• Chronic Idiopathic Myelofibrosis

  2007cites this paper
• Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia

  2007cites this paper
• Advances in the therapy of chronic idiopathic myelofibrosis.

  2006cites this paper
• T cell receptor excision circles (TRECs), CD4+, CD8+ and their CD45RO+ and CD45RA+ subpopulations in hepatitis C virus (HCV)‐HIV‐co‐infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy

  2006cites this paper
• Idiopathic myelofibrosis: pathogenesis to treatment

  2006cites this paper
• Conventional and new treatment options for myelofibrosis with myeloid metaplasia.

  2005cites this paper
• Modern management of myelofibrosis

  2005cites this paper
• Reticulin fibre content of bone marrow infiltrates of malignant non-Hodgkin's lymphomas (B-cell type, low malignancy) — a morphometric evaluation before and after therapy

  2005cites this paper
• The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis.

  2005cites this paper
• Synergistic Antiproliferative Effect of Recombinant Interferon-’ y With Recombinant Interferon-a on Chronic Myelogenous Leukemia Hematopoietic

  2005cites this paper
• Dynamics of Fibrosis in Chronic Idiopathic (Primary) Myelofibrosis During Therapy: A follow-up Study on 309 Patients

  2003cites this paper
• Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)

  2003cites this paper
• Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

  2003cites this paper
• Interferon-y Enhances Growth Factor-Dependent Proliferation of Clonogenic Cells in Acute Myeloblastic Leukemia

  2003cites this paper
• Mutational analysis of class III receptor tyrosine kinases (C‐KIT, C‐FMS, FLT3) in idiopathic myelofibrosis

  2003cites this paper
• Hoang clonogenic cells in acute myeloblastic leukemia Interferon-gamma enhances growth factor-dependent proliferation of

  2003cites this paper
• Cytogenetic and Molecular Genetic Aspects of Idiopathic Myelofibrosis

  2002cites this paper
• Chronic leukemias and lymphomas : biology, pathophysiology, and clinical management

  2002cites this paper
• CD34+ stem cells in chronic myeloproliferative disorders.

  2002cites this paper
• Direct signal transduction via functional interferon-alphabeta receptors in CD34+ hematopoietic stem cells.

  2002cites this paper
• In Vitro Development of Megakaryocytes and Platelets

  2002cites this paper
• Direct signal transduction via functional interferon-αβ receptors in CD34+ hematopoietic stem cells

  2001cites this paper
• Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia.

  2001cites this paper
• Therapy-Related Changes of CD34+ Progenitor Cells in Chronic Myeloid Leukemia: A Morphometric Study on Sequential Trephine Biopsies

  2001cites this paper
• Ineffectiveness of interferon-γ in the treatment of idiopathic myelofibrosis: a pilot study

  2001cites this paper
• Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.

  2001cites this paper
• Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study.

  2001cites this paper
• Research Report Therapy-Related Changes of CD34 1 Progenitor Cells in Chronic Myeloid Leukemia: A Morphometric Study on Sequential Trephine Biopsies

  2001cites this paper
• Comparative Effects of Interferon and Hydroxyurea on Bone Marrow Fibrosis in Chronic Myelogenous Leukemia

  2001cites this paper
• Diagnostic and clinical relevance of the number of circulating CD34 1 cells in myelofibrosis with myeloid metaplasia

  2001cites this paper
• Diagnostic and clinical relevance of the number of circulating CD34 1 cells in myelofibrosis with myeloid metaplasia

  2001cites this paper
• Interferon alpha in the treatment of polycythemia vera.

  2000cites this paper
• Interferon α2b directly induces fibroblast proliferation and transforming growth factor β secretion of macrophages

  2000cites this paper
• p95vav associates with the type I interferon (IFN) receptor and contributes to the antiproliferative effect of IFN-α in megakaryocytic cell lines

  2000cites this paper
• Lack of interferon-alpha-induced tyrosine phosphorylation of Vav proto-oncogene in patients with myelofibrosis with myeloid metaplasia.

  2000cites this paper
• [Polycythemia vera: current status of therapy].

  2000cites this paper
• Lack of interferon‐α‐induced tyrosine phosphorylation of Vav proto‐oncogene in patients with myelofibrosis with myeloid metaplasia

  2000cites this paper
• Interferon α in the treatment of polycythemia vera

  2000influential citation
• Circulating haemopoietic progenitor cells in primary and secondary myelofibrosis: relation to collagen and reticulin fibrosis

  1999cites this paper
• The role of interferon-alpha in the treatment of idiopathic myelofibrosis.

  1999cites this paper
• Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.

  1999cites this paper
• The role of interferon-α in the treatment of idiopathic myelofibrosis

  1999cites this paper
• Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

  1999cites this paper
• Pathogenesis of Idiopathic Myelofibrosis: A Review.

  1998cites this paper
• 3 Pathogenesis and management of idiopathic myelofibrosis

  1998cites this paper
• Effect of IFN-α on Normal Human Hematopoiesis: An Immunohistochemical and Morphometric Study on Trephine Biopsy Specimens

  1998cites this paper
• Pathogenesis and management of idiopathic myelofibrosis.

  1998cites this paper
• New drugs in essential thrombocythemia and polycythemia vera.

  1997cites this paper
• Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.

  1997cites this paper
• Idiopathic myelofibrosis: pathogenesis, natural history and management.

  1997cites this paper
• A case of interstitial pneumonitis associated with natural alpha-interferon therapy for myelofibrosis.

  1997cites this paper
• Interferon treatment in polycythaemia vera.

  1996cites this paper
• Interferon-α Inhibits CFU-GM Mobilization Following Chemotherapy and G-CSF Administration

  1996cites this paper
• Carboxy‐terminal peptides (C1–24 and C13–24 but not C1–13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin

  1996cites this paper
• Interferon-alpha inhibits CFU-GM mobilization following chemotherapy and G-CSF administration.

  1996cites this paper
• Biennial report on carcinogens. A work in progress.

  1995cites this paper
• α‐Interferon in myelofibrosis: a case report

  1994cites this paper
• PATHOGENESIS OF IDIOPATHIC MYELOFIBROSIS: PRESENT STATUS AND FUTURE DIRECTIONS

  1994cites this paper
• alpha-Interferon in myelofibrosis: a case report.

  1994cites this paper
• Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy.

  1993cites this paper
• The in vitro effects of interferon‐gamma, interferon‐alpha, and tumour‐necrosis factor‐alpha on erythroid burst‐forming unit growth in patients with non‐leukaemic myeloproliferative disorders

  1993cites this paper
• Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis. An immunohistological and morphometric study with comparison of corresponding bone marrow features.

  1992cites this paper
• Recombinant alpha‐interferon inhibits colony formation of bone marrow fibroblast progenitor cells (CFU‐F)

  1992cites this paper
• THE TREATMENT OF MYELOFIBROSIS WITH ALFA‐INTERFERON

  1991cites this paper
• Interferon-gamma enhances growth factor-dependent proliferation of clonogenic cells in acute myeloblastic leukemia.

  1991cites this paper
• Interferon-gamma in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.

  1991cites this paper
• Defective erythropoiesis in primary myelofibrosis associated with a chromosome 11 abnormality.

  1991cites this paper
• MEGA‐DOSE METHYLPREDNISOLONE FOR APLASTIC ANAEMIA

  1991cites this paper
• Interferon‐γin vivo reverses the increased platelet levels of platelet‐derived growth factor and transforming growth factor‐β in patients with myelofibrosis with myeloid metaplasia

  1991cites this paper
• Circulating progenitor cells in myelofibrosis: the effect of recombinant α2b interferon in vivo and in vitro

  1991cites this paper
• Identification and characterization of a functional receptor for interferon-gamma on a megakaryocytic cell line.

  1991cites this paper